WallStSmart
GLPG

Galapagos NV ADR

NASDAQ: GLPG · HEALTHCARE · BIOTECHNOLOGY

$27.86
-1.97% today

Updated 2026-04-29

Market cap
$1.91B
P/E ratio
5.00
P/S ratio
1.72x
EPS (TTM)
$5.69
Dividend yield
52W range
$25 – $38
Volume
0.2M

Galapagos NV ADR (GLPG) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-100.0%
Last 4 quarters
Revenue YoY growth
+1093.2%
Most recent quarter
EPS YoY growth
+3960.3%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+1.4%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+2.4%
2025-11-05
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-24$12.27+6119.7%$33.87$34.02+0.4%
2025-11-05$-3.54-903.1%$30.46$31.20+2.4%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.20$12.27+6119.7%$900.77M+1093.2%
2025-09-30$-0.35$-3.54-903.1%$71.16M+18.9%
2025-06-30$-0.23$-1.58-592.1%$65.29M-16.2%
2025-03-31$-0.18$-2.45-1261.1%$74.98M+20.1%
2024-12-31$0.28$0.30+8.0%$75.50M-136.1%
2024-09-30$-0.29$-0.83-186.2%$59.85M-50.1%
2024-06-30$-0.04$0.14+450.0%$77.87M-48.1%
2024-03-31$-0.13$1.40+1176.9%$62.43M+6.6%
2023-12-31$-1.18$2.39+302.5%$-209.12M
2023-09-30$-0.62$0.39+162.9%$120.03M
2023-06-30$-0.70$0.08+111.4%$149.95M
2023-03-31$-0.87$0.39+144.3%$58.57M

Frequently asked questions

Has Galapagos NV ADR beaten earnings estimates?
Galapagos NV ADR has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -100.0% over the last 4 quarters.
How does GLPG stock react to earnings?
GLPG stock has moved an average of +1.4% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.
What is Galapagos NV ADR's revenue growth rate?
Galapagos NV ADR reported year-over-year revenue growth of +1093.2% in its most recent quarter, with EPS growing +3960.3% year-over-year.